enlivex.com (ENLV) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Enlivex Therapeutics (ENLV) is developing immune recovery methods for oncology and sepsis, expanding its research portfolio to minimize risks. The absence of regular profits makes the business dependent on test outcomes and deals with industry behemoths. This daily price chart reflects the asset's value on GURU.Markets, which currently stands at 0.00. Meanwhile, laboratories are operating on schedule, utilizing modernized contractor capacities to scale the production of cell-based therapies.
Enlivex Therapeutics Ltd. - analytical breakdowns and key metrics (ENLV)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Enlivex Therapeutics|ENLV - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Enlivex Therapeutics Ltd.|ENLV - Company Cumulative Debt|Debts to Book Capitalization Enlivex Therapeutics|ENLV - Long-Term Debt|Company Short-Term Debt Enlivex Therapeutics|Quick Liquidity enlivex.com
- business earnings and investment ratios data:
ENLV - Company Net Income|Projected Future Earnings Enlivex Therapeutics|ENLV - Business Payback Period|Projected Price to Earnings Enlivex Therapeutics, Ltd.|ENLV - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Enlivex Therapeutics|ENLV - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Enlivex Therapeutics|ENLV - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months enlivex.com|ENLV - Earnings per share increase in current year|Expected earnings per share growth for next year Enlivex Therapeutics
- sales and revenue data:
Initial company analysis:Enlivex Therapeutics, Ltd. ENLV
AI-driven bioreactor automation reduces manual labor costs for Enlivex Therapeutics (ENLV), directly enhancing operational efficiency. By analyzing EV/EBITDA multiple fluctuations, an investor observes the ratio of total enterprise value, including debt, to earnings before interest, taxes, depreciation, and amortization, where low values indicate an undervalued asset but highlight the risk of high sensitivity of the company's valuation to any declines in operating income.
Competitor analysis
EV/EBITDA Multiple ARGX (argenx.com)|Total Company Value to Operating Income Before Depreciation Ratio biontech.de (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADMA Biologics Inc (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist Corp (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant, Inc.|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple grifols.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp (ADPT)|Celldex Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (auriniapharma.com)|BioCryst Pharmaceuticals Inc (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Therapeutics) - Enterprise Value to Operating Income Before Depreciation|PHVS: EV/EBITDA Multiple|ABCL (AbCellera Biologics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Intrexon PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group N.V. (PHAR)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|EV/EBITDA Multiple UPB (Upstream Pharma)|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Corp (GOSS) - Enterprise Value to EBITDA Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation SEPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|Savara Inc (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|Total Company Value to Operating Income Before Depreciation Ratio AnaptysBio Inc.|EV/EBITDA Multiple ATXS (Astria Therapeutics Inc)|enGene Holdings Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (aerovatetx.com)|Aclaris (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kyverna - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TLSA|Company Value to EBITDA Cabaletta Bio CABA|EV/EBITDA Multiple VTYX|Theratechnologies (THTX) - Enterprise Value to EBITDA Multiple|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|Eledon Pharmaceuticals (ELDN) - Company Value to EBITDA|Agenus, Inc - EV/EBITDA Multiple|Company Value to EBITDA climbbio.com|ZURA (Zura Bio Limited) - Enterprise Value to EBITDA Ratio|aTyr (ATYR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ADAG|IMA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Therapeutics (STTK)|Enterprise Value to EBITDA Ratio Equillium EQ|Connect Biopharma Holdings Limited - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|inflarx.de (IFRX) - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation X4 Pharmaceuticals XFOR|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization celularity.com|INMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BRNS|EV/EBITDA Multiple Kezar Life Sciences Inc (KZR)|EV/EBITDA Multiple SABS (SAB Biotherapeutics)|EV/EBITDA Multiple akaritx.com AKTX|QTTB: Enterprise Value to EBITDA Ratio|GOVX - EV/EBITDA Multiple|Edesa Biotech Corp (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carismatx.com|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Business Value to Operating Income Before Depreciation|Aptevo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ReShape Lifesciences|Enterprise Value to EBITDA Ratio REVB|Indaptus Corp (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scinai.com (SCNI)|Enterprise Value to EBITDA Ratio CalciMedica CALI|EV/EBITDA Multiple AFMD (affimed.com)|Allakos Inc. (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGMS (igmbio.com) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC BioPharm|Third Harmonic Bio Inc. (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
